SSY : VOLUNTARY ANNOUNCEMENT - UPDATE ON BUSINESS DEVELOPMENT AND PRODUCT DEVELOPMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

VOLUNTARY ANNOUNCEMENT

UPDATE ON BUSINESS DEVELOPMENT AND PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that Abidol, one of the products of the Group, was included in the "Diagnosis and Treatment Program for Novel Coronavirus Infected Pneumonia (Trial Version 8)" by the National Health Commission of the People's Republic of China on 18 August 2020. The Diagnosis and Treatment Program reconfirmed that Abidol was used in antiviral treatment.

The Board is also pleased to announce that Shijiazhuang No.4 Pharmaceutical Company Limited (a wholly owned subsidiary of the Company in China) has obtained the approval for drug production and registration for Rosuvastatin Calcium Tablets (10mg) from the National Medical Products Administration. Rosuvastatin calcium is under newly classified Type 4 chemical drug, and is mainly used in treatment of primary hypercholesterolemia or mixed dyslipidemia.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Company Secretary

Hong Kong, 19 August 2020

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.